Modulation of cytokine and nitric oxide by mesenchymal stem cell transfer in lung injury/fibrosis

Shin-Hwa Lee, An-Soo Jang, Young-Eun Kim, Ji-Yeon Cha, Tae-Hoon Kim, Seok Jung, Seong-Kyu Park, You-Kyoung Lee, Jong-Ho Won, Yong-Hoon Kim, Choon-Sik Park, Shin-Hwa Lee, An-Soo Jang, Young-Eun Kim, Ji-Yeon Cha, Tae-Hoon Kim, Seok Jung, Seong-Kyu Park, You-Kyoung Lee, Jong-Ho Won, Yong-Hoon Kim, Choon-Sik Park

Abstract

Background: No effective treatment for acute lung injury and fibrosis currently exists. Aim of this study was to investigate the time-dependent effect of bone marrow-derived mesenchymal stem cells (BMDMSCs) on bleomycin (BLM)-induced acute lung injury and fibrosis and nitric oxide metabolites and inflammatory cytokine production.

Methods: BMDMSCs were transferred 4 days after BLM inhalation. Wet/dry ratio, bronchoalveolar lavage cell profiles, histologic changes and deposition of collagen were analyzed.

Results: Nitrite, nitrate and cytokines were measured weekly through day 28. At day 7, the wet/dry ratio, neutrophilic inflammation, and amount of collagen were elevated in BLM-treated rats compared to sham rats (p = 0.05-0.002). Levels nitrite, nitrate, IL-1beta, IL-6, TNF-alpha, TGF-beta and VEGF were also higher at day 7 (p < 0.05). Degree of lymphocyte and macrophage infiltration increased steadily over time. BMDMSC transfer significantly reduced the BLM-induced increase in wet/dry ratio, degree of neutrophilic infiltration, collagen deposition, and levels of the cytokines, nitrite, and nitrate to those in sham-treated rats (p < 0.05). Fluorescence in situ hybridization localized the engrafted cells to areas of lung injury.

Conclusion: Systemic transfer of BMDMSCs effectively reduced the BLM-induced lung injury and fibrosis through the down-regulation of nitric oxide metabolites, and proinflammatory and angiogenic cytokines.

Figures

Figure 1
Figure 1
Flowcytometric Analysis of rat mesenchymal stem cells wased in the study. The cell surface marker phenotype of these MSCs was shown to be for CD45-, CD106-, CD44H+, CD90+, and CD11b+.
Figure 2
Figure 2
Variable differential potential of rat mesenchymal stem cells depending on culture method. (A) Culture-expanded mesenchymal stem cells showed a fibroblast-like morphology following culture expansion in vitro (×100). (B) Presence of adipocytes was demonstrated by oil red O staining of cytoplasmic inclusions of neutral lipids (×200). (C) Chondrocytes were demonstrated by toluidine blue staining (×100). (D) Calcium in the differentiated osteocytes was showed by Von Kossa staining (×100).
Figure 3
Figure 3
Schematic diagram of the experimental protocol. Specific pathogen-free, 6-week-old female SD rats (200-250 g body weight) were treated with 3 mg/kg bleomycin (BLM) dissolved in 5 ml of endotoxin-free water via inhalation. Bone marrow-derived mesenchymal stem cells (1 × 106) were administered via a tail vein on day 4 after BLM treatment. The rats were killed on days 0, 7, 14, 21, and 28. Lung specimens were obtained before and after bronchoalveolar lavage as described in the Materials and Methods.
Figure 4
Figure 4
Effect of BMDMSC transfer on body weight and survival rate. (A) BMDMSC transfer increased body weight gain in the bleomycin - treated rats. (B) Bleomycin - treated rats showed higher mortality rate compared to the sham - treated rats while BMDMSC transfer attenuated the mortality of the bleomycin - treated rats.
Figure 5
Figure 5
Effect of bone marrow-derived mesenchymal stem cell (BMDMSC) transfer on the bleomycin (BLM)-induced increase in the lung wet/dry ratio. The transfer of BMDMSCs significantly reduced the BLM-induced increase in the wet/dry ratio on day 7. * and ** indicate p < 0.05 and p < 0.01, respectively.
Figure 6
Figure 6
(A) Time-dependent changes in the inflammatory cell profile in bronchoalveolar lavage (BAL) fluid. Bleomycin (BLM)-induced increases in the number of neutrophils, lymphocytes, and macrophages in the BAL fluid were significantly reduced between days 7 and 28 by the transfer of BMDMSCs. * and ** indicate p < 0.05 and p < 0.01, respectively. (B) Effect of BMDMSC transfer on BLM-induced histologic changes in the lungs. Lung tissues were stained with hematoxylin & eosin on days 7, 14, 21, and 28. BLM treatment induced the intra-alveolar and interstitial infiltration of inflammatory cells. The extent of inflammation significantly decreased from day 7 to day 28 following BMDMSC transfer. Magnification = × 200.
Figure 7
Figure 7
Effect of BMDMSC transfer on collagen deposition in lung tissues and the total amount of soluble collagen in lung extracts. (A) Collagen deposition in the lungs was analyzed using Masson's Trichrome stain. (B) The Sircol collagen assay was used to measure the total amount of soluble collagen in lung tissue lysates. * and ** indicate p < 0.05 and p < 0.01, respectively.
Figure 8
Figure 8
Effect of bone marrow-derived mesenchymal stem cell (BMDMSC) transfer on the levels of IL-6 and TNF-α in bronchoalveolar lavage fluid and IL-1β, vascular endothelial growth factor (VEGF), and TGF-β in lung lysates. Bleomycin treatment significantly increased the levels of IL-1β (A), VEGF (B), IL-6 (C), TNF-α (D), and TGF-β (E) between days 7 and 28. The increases in IL-1β, VEGF, IL-6, TNF-α and TGF-β were significantly reduced by the transfer of BMDMSCs. * and ** indicate p < 0.05 and p < 0.01, respectively.
Figure 9
Figure 9
The effect of bone marrow-derived mesenchymal stem cell (BMDMSC) transfer on the bleomycin (BLM)-induced increases in nitrate and nitrite in lung extracts. BLM (n = 6) increased the nitrate (A) and nitrite levels (B) in lung extracts from day 7 to day 21; however, the effect was significantly reduced by BMDMSC transfer (n = 6). * and ** indicate p < 0.05 and p < 0.01, respectively.
Figure 10
Figure 10
Localization of the Y chromosome in bleomycin (BLM)-treated rats following bone marrow-derived mesenchymal stem cell transfer. A 2-μm-thick section of lung tissue from a BLM-treated rat hybridized with a fluorescein isothiocyanate-conjugated Y chromosome paint probe and counterstained with ethidium bromide is shown. (A) Bleomycin treated rats (n = 3). (B) Bone marrow-derived mesenchymal stem cell in recipient lungs under fluorescent microscope two weeks after BMDMSC injection in BMDMSC transfer rats (n = 3). The arrows indicate nuclei containing a Y chromosome. Magnification = 1000×. (C) Donor cells containing the Y chromosome zoomed out pictures of the lung. Magnification = 400×. (D) Localization of the cells containing the Y chromosome in serial section of lung tissue of BMDMSC transfer rats. H&E stain, magnification = 400×.

References

    1. Frutos-Vivar F, Nin N, Esteban A. Epidemiology of acute lung injury and acute respiratory distress syndrome. Curr Opin Crit Care. 2004;10:1–6. doi: 10.1097/00075198-200402000-00001.
    1. MacCallum NS, Evans TW. Epidemiology of acute lung injury. Curr Opin Crit Care. 2005;11:43–49. doi: 10.1097/00075198-200502000-00007.
    1. Jiang Y, Jahagirdar BN, Reinhardt RL, Schwartz RE, Keene CD, Ortiz-Gonzalez XR, Reyes M, Lenvik T, Lund T, Blackstad M, Du J, Aldrich S, Lisberg A, Low WC, Largaespada DA, Verfaillie CM. Pluripotency of mesenchymal stem cells derived from adult marrow. Nature. 2002;4186893:41–49. doi: 10.1038/nature00870.
    1. Krause DS, Theise ND, Collector MI, Henegariu O, Hwang S, Gardner R, Neutzel S, Sharkis SJ. Multi-organ, multi-lineage engraftment by a single bone marrow-derived stem cell. Cell. 2001;105:369–377. doi: 10.1016/S0092-8674(01)00328-2.
    1. Kotton DN, Ma BY, Cardoso WV, Sanderson EA, Summer RS, Williams MC, Fine A. Bone marrow-derived cells as progenitors of lung alveolar epithelium. Development. 2001;128:5181–5188.
    1. Ortiz LA, Gambelli F, McBride C, Gaupp D, Baddoo M, Kaminski N, Phinney DG. Mesenchymal stem cell engraftment in lung is enhanced in response to bleomycin exposure and ameliorates its fibrotic effects. Proc Natl Acad Sci USA. 2003;100:8407–8411. doi: 10.1073/pnas.1432929100.
    1. Yamada M, Kubo H, Kobayashi S, Ishizawa K, Numasaki M, Ueda S, Suzuki T, Sasaki H. Bone marrow-derived progenitor cells are important for lung repair after lipopolysaccharide-induced lung injury. J Immunol. 2004;172:1266–1272.
    1. Bowden DH. Unraveling pulmonary fibrosis; the bleomycin model. Lab Invest. 1984;50:487–488.
    1. Harrison JH Jr, Lazo JS. High dose continuous infusion of bleomycin in mice; a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther. 1987;243:1185–1194.
    1. Hagimoto N, Kuwano K, Nomoto Y, Kunitake R, Hara N. Apoptosis and expression of Fas/Fas ligand mRNA in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Cell Mol. 1997;16:91–101.
    1. Piguet PF, Collart MA, Grau GE, Kapanci Y, Vassalli P. Tumor necrosis factor/cachectin plays a key role in bleomycin-induced pneumopathy and fibrosis. J Exp Med. 1989;170:655–663. doi: 10.1084/jem.170.3.655.
    1. Hoyt DG, Lazo JS. Alterations in pulmonary mRNA encoding procollagens, fibronectin and transforming growth factor-beta precede bleomycin-induced pulmonary fibrosis in mice. J Pharmacol Exp Ther. 1988;246:765–771.
    1. Fehrenbach H. Alveolar epithelial type II cell; defender of the alveolus revisited. Respir Res. 2001;2:33–46. doi: 10.1186/rr36.
    1. Yen CC, Yang SH, Lin CY, Chen CM. Stem cells in the lung parenchyma and prospects for lung injury therapy. Eur J Clin Invest. 2006;36:310–309. doi: 10.1111/j.1365-2362.2006.01638.x.
    1. Ortiz LA, Dutreil M, Fattman C, Pandey AC, Torres G, Go K, Phinney DG. Interleukin 1 receptor antagonist mediates the antiinflammatory and antifibrotic effect of mesenchymal stem cells during lung injury. Proc Natl Acad Sci USA. 2007;104:11002–11007. doi: 10.1073/pnas.0704421104.
    1. Olman MA, White KE, Ware LB, Simmons WL, Benveniste EN, Zhu S, Pugin J, Matthay MA. Pulmonary edema fluid from patients with early lung injury stimulates fibroblast proliferation through IL-1 beta-induced IL-6 expression. J Immunol. 2004;172:2668–2677.
    1. Meduri GU, Kohler G, Headley S, Tolley E, Stentz F, Postlethwaite A. Inflammatory cytokines in the BAL of patients with ARDS; persistent elevation over time predicts poor outcome. Chest. 1995;108:1303–1314. doi: 10.1378/chest.108.5.1303.
    1. Madtes DK, Rubenfeld G, Klima LD, Milberg JA, Steinberg KP, Martin TR, Raghu G, Hudson LD, Clark JG. Elevated transforming growth factor-alpha levels in bronchoalveolar lavage fluid of patients with acute respiratory distress syndrome. Am J Respir Crit Care Med. 1998;158:424–430.
    1. Kolb M, Margetts PJ, Anthony DC, Pitossi F, Gauldie J. Transient expression of IL-1β induces acute lung injury and chronic repair leading to pulmonary fibrosis. J Clin Invest. 2001;107:1529–1536. doi: 10.1172/JCI12568.
    1. Henke C, Marineili W, Jessuurun J, Fox J, Harms D, Peterson M, Chiang L, Doran P. Macrophage production of basic fibroblas growth factor in the fibroproliferative disorder of alveolar fibrosis after lung injury. Am J Pathol. 1993;143:1189–1199.
    1. Lahm T, Crisostomo PR, Markel TA, Wang M, Lillemoe KD, Meldrum DR. The critical role of vascular endothelial growth factor in pulmonary vascular remodeling after lung injury. Shock. 2007;28:4–14. doi: 10.1097/shk.0b013e31804d1998.
    1. Gazdhar A, Fachinger P, van Leer C, Pierog J, Gugger M, Friis R, Schmid RA, Geiser T. Gene transfer of hepatocyte growth factor by electroporation reduces bleomycin-induced lung fibrosis. Am J Physiol Lung Cell Mol Physiol. 2007;292:L529–536. doi: 10.1152/ajplung.00082.2006.
    1. Rojas M, Xu J, Woods CR, Mora AL, Spears W, Roman J, Brigham L. Bone marrow derived mesenchymal stem cells in repair of the injured lung. Am J respire Cell Mol Biol. 2005;33:145–152. doi: 10.1165/rcmb.2004-0330OC.
    1. Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors; is it possible to improve upon G-CSF? Bone Marrow Transplant. 2007;39:577–588. doi: 10.1038/sj.bmt.1705616.
    1. Burnham EL, Taylor WR, Quyyumi AA, Rojas M, Brigham KL, Moss M. Increased circulating endothelial progenitor cells are associated with survival in acute lung injury. Am J Respir Crit Care Med. 2005;172:854–860. doi: 10.1164/rccm.200410-1325OC.
    1. Cheson BD. In: Cancer principles and practice of oncology. De Vita Jr. VT, Hellmann S, Rosenberg AS, editor. Lippincott Willians & Wilkins; 2001. Pharmacology of cancer chemotherapy; miscellaneous chemotherapeutic agents; pp. 452–459.
    1. Hay J, Shahzeidi S, Laurent G. Mechanisms of bleomycin-induced lung damage. Arch Toxicol. 1991;65:81–94. doi: 10.1007/BF02034932.
    1. Boyaci H, Maral H, Turan G, Basyigit I, Dillioglugil MO, Yildiz F, Tugay M, Pala A, Ercin C. Effects of erdosteine on bleomycin-induced lung fibrosis in rats. Mol Cell Biochem. 2006;281:129–137. doi: 10.1007/s11010-006-0640-3.
    1. Gaston B, Drazen JM, Loscalzo J, Stamler JS. The biology of nitrogen oxides in the airways. Am J Respir Crit Care Med. 1994;149:538–551.
    1. Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, Matalon S. Quantification of nitrotyrosine levels in lung secretions of patients and animals with acute lung injury. J Clin Invest. 1994;94:2407–2413. doi: 10.1172/JCI117607.
    1. Jang AS, Lee JU, Choi IS, Park KO, Lee JH, Park SW, Park CS. Expression of nitric oxide synthase, aquaporin 1 and aquaporin 5 in rat after bleomycin inhalation. Intensive Care Med. 2004;30:489–495. doi: 10.1007/s00134-003-2129-9.
    1. Meirelles Lda S, Nardi NB. Murine marrow-derived mesenchymal stem cell; isolation, in vitro expansion, and characterization. Br J Haematol. 2003;123:702–711. doi: 10.1046/j.1365-2141.2003.04669.x.
    1. Choi S, Park M, Kim J, Hwang S, Park S, Lee Y. The role of mesenchymal stem cells in the functional improvement of the chronic renal failure. Stem Cells Dev. 2009;183:521–9. doi: 10.1089/scd.2008.0097.
    1. Chang JY, Kessler HP. Masson trichrome stain helps differentiate myofibroma from smooth muscle lesions in the head and neck region. J Formos Med Assoc. 2008;10710:767–73. doi: 10.1016/S0929-6646(08)60189-8.
    1. McBride C, Gaupp D, Phinney DG. Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by real-time PCR. Cytotherapy. 2003;5:7–18. doi: 10.1080/14653240310000038.
    1. Kooy NW, Royall JA, Ye YZ, Kelly DR, Beckman JS. Evidence for in vivo peroxynitrite production in human acute lung injury. Am J Respir Crit Care Med. 1995;151:1250–1254.
    1. Marshall RP, Bellingan G, Webb S, Puddicombe A, Goldsack N, McAnulty RJ, Laurent GJ. Fibroproliferation occurs early in the acute respiratory distress syndrome and impacts on outcome. Am J Respir Crit Care Med. 2000;162:1783–1788.
    1. Kaner RJ, Ladetto JV, Singh R, Fukuda N, Matthay MA, Crystal RG. Lung overexpression of the vascular endothelial growth factor gene induces pulmonary edema. Am J Respir Cell Mol Biol. 2000;22:657–664.
    1. Karmpaliotis D, Kosmidou I, Ingenito EP, Hong K, Malhotra A, Sunday ME, Haley KJ. Angiogenic growth factors in the pathophysiology of a murine model of acute lung injury. Am J Physiol Lung Cell Mol Physiol. 2002;283:L585–L595.
    1. Janes KA, Gaudet S, Albeck JG, Nielsen UB, Lauffenburger DA, Sorger PK. The response of human epithelial cells to TNF involves an inducible autocrine cascade. Cell. 2006;124:1225–1239. doi: 10.1016/j.cell.2006.01.041.
    1. Kuwano K, Nakashima N, Inoshima I, Hagimoto N, Fujita M, Yoshimi M, Maeyama T, Hamada N, Watanabe K, Hara N. Oxidative stress in lung epithelial cells from patients with idiopathic interstitial pneumonias. Eur Respir J. 2003;21:232–240. doi: 10.1183/09031936.03.00063203.
    1. Bellocq A, Azoulay E, Marullo S, Flahault A, Fouqueray B, Philippe C, Cadranel J, Baud L. Reactive oxygen and nitrogen intermediates increase transforming growth factor-beta1 release from human epithelial alveolar cells through two different mechanisms. Am J Respir Cell Mol Biol. 1999;21:128–136.
    1. Barcellos-Hoff MH, Dix TA. Redox-mediated activation of latent transforming growth factor-beta 1. Mol Endocrinol. 1996;10:1077–1083. doi: 10.1210/me.10.9.1077.
    1. Lakari E, Soini Y, Saily M, Koistinen P, Paakko P, Kinnula VL. Inducible nitric oxide synthase, but not xanthine oxidase, is highly expressed in interstitial pneumonias and granulomatous diseases of human lung. Am J Clin Pathol. 2002;117:132–142. doi: 10.1309/W7T9-HW9V-V94B-R9KM.
    1. Gupta N, Su X, Popov B, Lee JW, Serikov V, Matthay MA. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol. 2007;179:1855–1863.
    1. Schrier DJ, Kunkel RG, Phan SH. The role of strain variation in murine bleomycininduced pulmonary fibrosis. Am Rev Respir Dis. 1983;127:63–66.
    1. Park CS, Chung SW, Ki SY, Lim GI, Uh ST, Kim YH, Choi DI, Park JS, Lee DW, Kitaichi M. Increased levels of interleukin-6 are associated with lymphocytosis in bronchoalveolar lavage fluids of idiopathic nonspecific interstitial pneumonia. Am J Respir Crit Care Med. 2000;1623(Pt 1):1162–1168.
    1. Prockop DJ. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 1997;276:71–74. doi: 10.1126/science.276.5309.71.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する